Your Daily Psychedelics & Therapy Briefing
Psilocybin, MDMA-assisted therapy, clinical trials, and the regulated psychedelic medicine movement. Get the latest psychedelics & therapy developments delivered to your inbox every morning. AI-powered, personalized, and grounded in real sources.
FDA Outlines Preliminary Thinking for Ibogaine Trials Amidst Industry Strategy Updates
The U.S. Food and Drug Administration (FDA) has shared its preliminary thinking on early-stage ibogaine trials, suggesting a single dose in an intensively monitored inpatient setting for adults with opioid use disorder or post-traumatic stress disorder. This guidance, reported on October 16, 2026, emphasizes strict safety measures due to known cardiac risks, such as QTc prolongation, and follows the agency's earlier request for public feedback on ibogaine's safety and oversight.
Optimi Health presented at The ThinkEquity Conference on October 15, 2026, detailing its strategy as a low-cost, vertically integrated psychedelic medicine company with commercial sales in Australia and a long-term path to U.S. approval. The company highlighted that a typical psilocybin treatment session lasts four to six hours in a calm clinical setting, with lower doses (1 to 5 milligrams) potentially improving focus without strong perceptual effects.
The Bottom Line
Regulatory bodies are increasingly defining the parameters for psychedelic therapies, with the FDA outlining specific safety protocols for ibogaine trials, while companies like Optimi Health are refining their operational and clinical strategies to navigate this evolving landscape.
Get Psychedelics & Therapy in your inbox every morning
Join readers who start their day with an AI-powered briefing on psychedelics & therapy and the topics they care about most — fully sourced and ready in 5 minutes.
Start your free trial7-day free trial · No credit card required
Related Briefings
Mental Health
Therapy research, workplace wellness, anxiety and depression treatments, and destigmatization efforts.
Pharmaceuticals
Drug approvals, clinical trials, pricing debates, and the pharmaceutical industry landscape.
Biotechnology
Gene editing, drug development, clinical trials, and the science of engineering biology.
Pick your topics
Psychedelics & Therapy, plus anything else you follow
We research overnight
AI synthesizes real-time sources while you sleep
Read in 5 minutes
Cited, structured, no fluff — in your inbox every morning